UPJOHN Company Profile

✉ Email this page to a colleague

UPJOHN has thirteen approved drugs.

There are three US patents protecting UPJOHN drugs.

There are thirty-three patent family members on UPJOHN drugs in thirty-three countries and thirty-nine supplementary protection certificates in thirteen countries.

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Upjohn	LYRICA	pregabalin	CAPSULE;ORAL	021446-005	Dec 30, 2004	AB	RX	Yes	No		⤷ Subscribe				⤷ Subscribe
Upjohn	LYRICA	pregabalin	CAPSULE;ORAL	021446-004	Dec 30, 2004	AB	RX	Yes	No		⤷ Subscribe				⤷ Subscribe
Upjohn	EFFEXOR XR	venlafaxine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	020699-002	Oct 20, 1997	AB	RX	Yes	No		⤷ Subscribe				⤷ Subscribe
Upjohn	LYRICA CR	pregabalin	TABLET, EXTENDED RELEASE;ORAL	209501-001	Oct 11, 2017	AB	RX	Yes	No	9,144,559*PED	⤷ Subscribe			Y	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Upjohn	DETROL	tolterodine tartrate	TABLET;ORAL	020771-002	Mar 25, 1998	5,550,269*PED	⤷ Subscribe
Upjohn	INSPRA	eplerenone	TABLET;ORAL	021437-003	Sep 27, 2002	6,410,054*PED	⤷ Subscribe
Upjohn	LIPITOR	atorvastatin calcium	TABLET;ORAL	020702-004	Apr 7, 2000	5,969,156*PED	⤷ Subscribe
Upjohn	CELEBREX	celecoxib	CAPSULE;ORAL	020998-001	Dec 31, 1998	5,972,986*PED	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Tablets	25 mg and 50 mg	➤ Subscribe	2006-09-27
➤ Subscribe	Extended-release Capsules	2 mg and 4 mg	➤ Subscribe	2007-07-30
➤ Subscribe	Capsules	50 mg	➤ Subscribe	2008-03-21
➤ Subscribe	Oral Solution	20 mg/mL	➤ Subscribe	2010-05-19
➤ Subscribe	Extended-release Tablets	82.5 mg and 165 mg	➤ Subscribe	2018-02-02
➤ Subscribe	Extended-release Tablets	82.5 mg and 165 mg	➤ Subscribe	2018-02-02
➤ Subscribe	Tablets	20 mg and 40 mg	➤ Subscribe	2010-03-29
➤ Subscribe	Extended-release Tablets	37.5 mg, 75 mg and 150 mg	➤ Subscribe	2007-05-03
➤ Subscribe	Capsules	25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg	➤ Subscribe	2008-12-30
➤ Subscribe	Extended-release Tablets	330 mg	➤ Subscribe	2018-01-29
➤ Subscribe	Extended-release Tablets	330 mg	➤ Subscribe	2018-01-29

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration
Eurasian Patent Organization	012377	⤷ Subscribe
Dominican Republic	P2006000241	⤷ Subscribe
Brazil	PI0618211	⤷ Subscribe
Guatemala	200600474	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration

Subscribe to access the full database, or Subscribe
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0364417	C970039	Netherlands	⤷ Subscribe	PRODUCT NAME: [1R-[1 ALPHA (Z),2 BETA(R*),3 ALPHA,5ALPHA]]-7-[3,5-DIHYDROXY-2-(3-HYDROXY-5- FENYLPENTYL)CYCLOPENTYL]-5-HEPTEENZUUR, DESGEWENST IN DE VORM VAN EEN ZOUT OF EEN ESTER, IN HET BIJZONDER LATANOPROSTUM; NAT. REGISTRATION NO/DATE: RVG 21304 19970610; FIRST REGISTRATION: SE 12716 19960718
0364417	97C0111	Belgium	⤷ Subscribe	PRODUCT NAME: LATANOPROSTUM; NAT. REGISTRATION NO/DATE: 277 IS 271 F 13 19970617; FIRST REGISTRATION: SE 12716 1996071
0641330	CR 2004 00036	Denmark	⤷ Subscribe	PRODUCT NAME: PREGABALIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/04/279/001-025 20040706
0720599	92545	Luxembourg	⤷ Subscribe	PRODUCT NAME: EZETIMIBE EN COMBINAISON AVEC ATORVASTATINE OU LEURS SELS PHARMACEUTIQUEMENT ACCEPTEES, Y COMPRIS ATORVASTATINE SOUS FORME D'ATORVASTATINE CALCIQUE TRIHYDRATEE; FIRST REGISTRATION: 20140910
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.